Developmental surveillance and screening is recommended for all children under five years of age, especially for those from at-risk populations such as First Nations children. No review to date has, however, evaluated the use of developmental screening tools with First Nations children. This review aimed to examine and synthesise the literature on developmental screening tools developed for, or used with, First Nations populations children aged five years or younger. A PRISMA-compliant systematic review was performed in the PsychInfo, PubMed, and Embase databases. Additional searches were also undertaken. In total 444 articles were identified and 13 were included in the final review. Findings indicated that several developmental screening tools have been administered with First Nations children. Most tools, however, have only been evaluated in one study. Results also found that no studies evaluated actions taken following positive screening results. More research evaluating the accuracy, acceptability, and feasibility of using developmental screeners with First Nations children is required before widespread implementation of developmental screening in clinical settings with First Nations children is recommended.

Inflammatory bowel disease (IBD) is a chronic debilitating condition, hallmarked by persistent inflammation of the gastrointestinal tract. Despite recent advances in clinical treatments, the aetiology of IBD is unknown, and a large proportion of patients are refractory to pharmacotherapy. Understanding IBD immunopathogenesis is crucial to discern the cause of IBD and optimise treatments. Mas‐related G protein‐coupled receptors (Mrgprs) are a family of approximately 50 G protein‐coupled receptors that were first identified over 20 years ago. Originally known for their expression in skin nociceptors and their role in transmitting the sensation of itch in the periphery, new reports have described the presence of Mrgprs in the gastrointestinal tract. In this review, we consider the impact of these findings and assess the evidence that suggests that Mrgprs may be involved in the disrupted homeostatic processes that contribute to gastrointestinal disorders and IBD.

ObjectiveTo examine and synthesize the literature on the use of universal developmental screening and surveillance tools in high-income countries in relation to (1) psychometric properties; (2) knowledge, acceptability, and feasibility of tools; and (3) follow-up taken following screening/surveillance.MethodA PRISMA-compliant systematic review was performed in the PsychInfo, PubMed, and Embase databases. Studies published in the English language were included if they reported results evaluating a universal developmental screening or surveillance measurement tool. Articles on service providers’ and/or parents’ views on developmental screening were also included. Two independent reviewers extracted data and assessed for risk of bias using the Mixed Methods Appraisal Tool and the Quality Assessment of Diagnostic Accuracy Studies Tool. Results were synthesized qualitatively.ResultsInitial searches identified 2,078 articles, of which 52 were included in the final review. Findings showed that several articles assessing the accuracy of screening tools have been published, and together, they suggest that the accuracy of screening tools varies across cultures and countries. Furthermore, available literature indicated that administering universal developmental screening tools was feasible and acceptable, though only a small number of studies are available. Results also showed a limited number of studies looking at actions taken following positive screening results.ConclusionAs the evidence stands, more research assessing the acceptability, feasibility, and accuracy of developmental screeners, is needed.Systematic review registrationThis review has been registered with the University of York Centre for Reviews and Dissemination (PROSPERO; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=337320, registration number CRD42022337320).